Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance

Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance

Docetaxel—a taxane-based chemotherapeutic agent—was the first treatment to demonstrate significant improvements in overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, the response to docetaxel is generally short-lived, and relapse eventually occurs due to t...

Full description

Bibliographic Details
Main Authors: Thiago S. Lima, Diego Iglesias-Gato, Luciano D.O. Souza, Jan Stenvang, Diego S. Lima, Martin A. Røder, Klaus Brasso, José M.A. Moreira
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
prostate cancer
docetaxel resistance
cellular models
androgen independence
Online Access:https://www.mdpi.com/2072-6694/13/6/1290

Internet

https://www.mdpi.com/2072-6694/13/6/1290

Similar Items